^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Promitil (pegylated liposomal mitomycin-c prodrug)

    i
    Other names: LPMX-1, PL-MLP, LPMX1, PLMLP, LPMX 1, PL MLP
    Associations

    News

    Trials
    Company:
    LipoMedix
    Drug class:
    DNA synthesis inhibitor, Alkylating agent
    Related drugs:
    Associations

    News

    Trials
    10d
    Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed After Therapy (clinicaltrials.gov)
    P2, N=19, Terminated, Lipomedix Pharmaceuticals Inc. | Trial completion date: Jan 2027 --> Jan 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2026 --> Jan 2026; Sponsor decision
    Trial completion date • Trial termination • Trial primary completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    Promitil (pegylated liposomal mitomycin-c prodrug)
    9ms
    Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed After Therapy (clinicaltrials.gov)
    P2, N=20, Active, not recruiting, Lipomedix Pharmaceuticals Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BRCA (Breast cancer early onset)
    |
    Promitil (pegylated liposomal mitomycin-c prodrug)
    over1year
    Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed After Therapy (clinicaltrials.gov)
    P2, N=20, Recruiting, Lipomedix Pharmaceuticals Inc.
    New P2 trial
    |
    BRCA (Breast cancer early onset)
    |
    Promitil (pegylated liposomal mitomycin-c prodrug)